KR20210086660A - 낭포성 섬유증을 치료하기 위한 아미노산 조성물 및 방법 - Google Patents

낭포성 섬유증을 치료하기 위한 아미노산 조성물 및 방법 Download PDF

Info

Publication number
KR20210086660A
KR20210086660A KR1020217015464A KR20217015464A KR20210086660A KR 20210086660 A KR20210086660 A KR 20210086660A KR 1020217015464 A KR1020217015464 A KR 1020217015464A KR 20217015464 A KR20217015464 A KR 20217015464A KR 20210086660 A KR20210086660 A KR 20210086660A
Authority
KR
South Korea
Prior art keywords
cftr
amino acids
free amino
certain embodiments
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217015464A
Other languages
English (en)
Korean (ko)
Inventor
사다시반 비드야사가르
아스트리드 그로쉬
샤오동 쑤
샨샨 린
스리카라 프라바카란
Original Assignee
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 filed Critical 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드
Publication of KR20210086660A publication Critical patent/KR20210086660A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020217015464A 2018-10-30 2019-10-30 낭포성 섬유증을 치료하기 위한 아미노산 조성물 및 방법 Pending KR20210086660A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752847P 2018-10-30 2018-10-30
US62/752,847 2018-10-30
PCT/US2019/058954 WO2020092639A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Publications (1)

Publication Number Publication Date
KR20210086660A true KR20210086660A (ko) 2021-07-08

Family

ID=70464502

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217015464A Pending KR20210086660A (ko) 2018-10-30 2019-10-30 낭포성 섬유증을 치료하기 위한 아미노산 조성물 및 방법

Country Status (10)

Country Link
US (1) US12220400B2 (https=)
EP (1) EP3873453A4 (https=)
JP (2) JP7689492B2 (https=)
KR (1) KR20210086660A (https=)
CN (1) CN113164425A (https=)
AU (2) AU2019370363B2 (https=)
BR (1) BR112021008395A2 (https=)
CA (1) CA3116015A1 (https=)
MX (1) MX2021005113A (https=)
WO (1) WO2020092639A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177780A1 (en) * 2020-05-29 2021-12-02 University Of Florida Research Foundation, Inc. Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
WO2002098405A1 (fr) 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
ITTO20010804A1 (it) 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
WO2003055481A1 (en) 2001-12-25 2003-07-10 Ajinomoto Co., Inc. Organ fibrosis inhibitors
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP1513870A4 (en) * 2002-05-31 2006-06-07 Childrens Hosp Medical Center CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL FOR TREATING MUCOVISCIDOSE AND TECHNIQUES AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THESE
AU2003901316A0 (en) * 2003-03-21 2003-04-03 The Royal Alexandra Hospital For Children Regulation of cell surface proteins
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
US8389736B2 (en) 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
ITTO20080443A1 (it) 2008-06-06 2009-12-07 Professional Dietetics Srl Composizioni comprendenti amminoacidi, con attivita' pro-angiogenica
EP2664326B1 (en) 2012-05-17 2017-11-01 I.E.R.F.C. European Institute for Cystic Fibrosis Research Combined therapy for cystic fibrosis
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016191263A1 (en) 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis
CA3001099A1 (en) * 2015-10-09 2017-04-13 Abbvie S.A.R.L. Potentiator-corrector combinations useful in the treatment of cystic fibrosis
MA45397A (fr) * 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr

Also Published As

Publication number Publication date
AU2019370363A1 (en) 2021-05-13
JP2022506044A (ja) 2022-01-17
AU2025248660A1 (en) 2025-10-30
BR112021008395A2 (pt) 2021-09-28
EP3873453A4 (en) 2022-08-03
US12220400B2 (en) 2025-02-11
JP7689492B2 (ja) 2025-06-06
CN113164425A (zh) 2021-07-23
JP2025128185A (ja) 2025-09-02
CA3116015A1 (en) 2020-05-07
MX2021005113A (es) 2021-06-15
US20210393584A1 (en) 2021-12-23
AU2019370363B2 (en) 2025-07-10
WO2020092639A1 (en) 2020-05-07
EP3873453A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
JP2025128185A (ja) 喘息またはｃｏｐｄを治療するためのアミノ酸組成物及び方法
Czikora et al. A novel tumor necrosis factor–mediated mechanism of direct epithelial sodium channel activation
Kim et al. Calcium‐sensing receptor (CaSR) as a novel target for ischemic neuroprotection
US20110111014A1 (en) Methods and compositions for treatment of neurological disorders
US20020115619A1 (en) Compositions and methods for treatment of cystic fibrosis
TW201212936A (en) Methods and compositions for intrathecal delivery of Alpha N-acetyglucosaminidase
JP7482914B2 (ja) ホモシスチン尿症の治療する組成物および方法
CN107405382A (zh) 用于改善认知的方法和组合物
KR20090123873A (ko) 수초형성 및 올리고덴드로사이트 분화 촉진을 위한 세마포린 ６ａ의 용도
US11351225B2 (en) Methods for modulating development and function of photoreceptor cells
WO2007109648A2 (en) Compositions and methods for modulating store-operated calcium entry
JP2022517255A (ja) 上皮または内皮バリア機能の改善
WO2019070759A1 (en) AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
US11413325B2 (en) Neuronal survival and axonal regeneration through increasing mitochondrial motility
JP7630540B2 (ja) 神経保護ペプチド
BR112020012972A2 (pt) uso de derivados de álcool 1-fenil-2-piridinil alquílico para tratar fibrose cística
Ren et al. Nicotinic acetylcholine receptor (nAChR) dependent chorda tympani taste nerve responses to nicotine, ethanol and acetylcholine
RU2776477C2 (ru) Применение производных 1-фенил-2-пиридинилалкилового спирта при лечении муковисцидоза
US5834421A (en) Methods and compositions for treating cystic fibrosis
KR20250114044A (ko) 만성 호흡기 질환 치료약
WO2024036044A1 (en) Compositions and methods for treating and preventing metabolic disorders
KR20250040552A (ko) 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술
CN118490828A (zh) Oxgr1受体激动剂促进肺黏液纤毛清除系统功能
Tjälve et al. The Olfactory Pathway as
Hebert Age-related changes in nigrostriatal and mesolimbic dopaminergic neuronal function in the Fischer 344 rat

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000